The reduced risk of ER-positive breast cancer we observed with daily aspirin use is consistent with the mechanism of action of aspirin (but not nonaspirin NSAIDs), which permanently inactivates COX-2 [29], potentially reducing breast cancer risk via multiple pathways, including suppression of estrogen synthesis by decreased aromatase activity [28]. The gene discussed is CYP19A1; the disease is breast carcinoma.